Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale-Reference-Cited by-同舟云学术

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale

Published:2017-06-17 Issue:1 Volume:16 Page:
ISSN:1476-511X
Container-title:Lipids in Health and Disease
language:en
Short-container-title:Lipids Health Dis

Author:

Teramoto Tamio,Kondo Akira,Kiyosue Arihiro,Harada-Shiba Mariko,Ishigaki Yasushi,Tobita Kimimasa,Kawabata Yumiko,Ozaki Asuka,Baccara-Dinet Marie T.,Sata Masataka

Funder

Sanofi

Regeneron Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1186/s12944-017-0513-7.pdf

Reference42 articles.

1. Estimates for 2000–2015: cause-specific mortality [ http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html ].

2. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -- 2012. J Atheroscler Thromb. 2013;20:603–15.